DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Adrenergic receptors (Cont.):
beta, 201, 205–207
polymorphisms, 160t
subtypes, 204t
interference with, 210, 212
localization of, 209
physiological basis of function of,
281–282
promoters, 211
representative agents, 206t
structure, 205
Adrenergic transmission, 194–210
adrenergic receptors, physiological
basis of function of, 281–282
Adrenocortical steroids. See
Adrenocorticosteroids
Adrenocortical suppressants, for
neoplastic disease,
1668t–1670t
Adrenocorticosteroids, 1215–1235,
1668t–1670t
absorption of, 1222–1223
antiinflammatory and
immunosuppressive actions
of, 1221–1222
carbohydrate metabolism and, 1219
cardiovascular system and,
1220–1221
central nervous system and, 1221
diagnostic uses of, 1235
electrolyte balance and, 1220
excretion of, 1223
history of, 1209–1210
inhibitors of biosynthesis and action
of, 1235–1236
lipid metabolism and, 1219–1220
mechanism of action, 1007,
1216–1217
metabolism of, 1223
osteoporosis and, 1227
physiological actions of,
1215–1222, 1216t
protein metabolism and, 1219
replacement therapy, 1228
for rheumatic disorders, 1232
skeletal muscle and, 1221
structure-activity relationships of,
1216t, 1223–1224
therapeutic uses of, 1007–1008,
1227–1235
for neoplastic disease,
1668t–1670t
toxicity of, 1224–1227
transport, 1223
water balance and, 1220
Adrenocorticotropic hormone (ACTH)
absorption and fate of, 1215
actions in adrenal cortex, 1210–1211
arginine vasopressin and,
1213–1214
assays for, 1214
extraadrenal effects of, 1213
mechanism of action of, 1211–1213
secretion of, regulation of, 1213
stress response and, 1214
therapeutic uses of, 1214–1215
Adrenocorticotropic hormone (ACtH),
1106t
Adrenoleukodystrophy, 104t
Adriamycin, 128t
Adsorption, of poison, 84
ADT. See Androgen deprivation
therapy (ADT)
Adverse Event Reporting System, 79
Adverse reactions
difficulty in detecting, 10
reporting of, 10
Adverse responses
clearance organs and, 92f
epidemiology of, 79–80
target organs and, 92f
transporters and, 91–93, 92f
Advertising, drug, 1883
ADVIL (ibuprofen), 988
AERIUS (desloratadine), 922t
Afferent fibers, visceral, 171–172
Affinity, 44–45
Aflatoxin B 1
, 1859–1860
Aflibercept, 1738–1739
African Americans, population specific
polymorphisms in, 150
Afterdepolarizations, 820
Afterload, 756
pharmacological modification, 756
Age
and dyslipidemia treatment, 890
and risk for coronary heart disease,
887t
AGENERASE (amprenavir), 1626t
Age-related macular degeneration
(ARMD), drug treatment,
1793–1794
Aggression, 5-HT and, 343
Agonism, quantification of, 46
Agranulocytosis, sulfonamide-induced,
1467
AHR. See Aryl hydrocarbon receptor
(AHR)
AIDS (acquired immune deficiency
syndrome), 1756
AIs. See Aromatase inhibitors
Akathisia, antipsychotic-related, 437t
AKPRO (dipivefran), 1786t
ALA. See Aminolevulinic acid
ALAWAY (ketotifen fumarate), 1789
Albendazole, pharmacokinetics of,
1810t
Albumin
distribution and, 24
plasma-protein binding and, 1803
Albuterol, 291, 292f
adrenergic receptors and, 206t
arrhythmias caused by, 832
pharmacokinetics of, 1810t
polymorphisms and response to,
160t
structure of, 279t
Alclometasone dipropionate
cream, 1225t
ointment, 1225t
Alcohol(s), 632–639. See also Ethanol
and acitretin, etrectinate produced
by, 1812
metabolism of, 125t
Alcohol dehydrogenase, 125t,
630–632, 694f
Alcoholism, pharmacotherapy of,
642–644
Alcohol use, and dyslipidemia, 890t
ALDACTAZIDE, 695
ALDACTONE (spironolactone), 693t,
1841
ALDARA (imiquimod), 1596t, 1818,
1823
Aldedyhde metabolism, 125t
Aldehyde dehydrogenase, 125t,
630–632, 694f
Aldesleukin, 1749
ALDOMET (methyldopa), 1847
Aldosterone. See also Reninangiotensin-aldosterone
axis
release, angiotensin II and, 729
renal effects of, 694f
synthesis of, heparin and, 859
Aldosterone antagonists, 692, 793
Aldosterone-induced proteins (AIPs),
692
Alefacept, 1019, 1824, 1825t, 1826f
Alemtuzumab, 1745, 1746t
dosage and administration of, 1747t,
1748
mechanism of action of, 1748
pharmacokinetics of, 1748
therapeutic uses of, 1748
toxicity of, 1747t, 1748
1993
INDEX